Chai Discovery在OpenAI的支持下,筹集了13000万美元,用于提升其AI药物发现平台。 Chai Discovery, backed by OpenAI, raised $130M to boost its AI drug discovery platform.

由OpenAI支持的AI驱动的生物技术启动企业Chai Discovery在B系列回合中筹集了1.3亿美元, Chai Discovery, an AI-driven biotech startup backed by OpenAI, has raised $130 million in a Series B round, valuing the company at $1.3 billion. 这笔资金由Oak HC/FT和General Calyst牵头,使筹集的资本总额超过2.25亿美元。 The funding, led by Oak HC/FT and General Catalyst, brings total capital raised to over $225 million. 该公司利用其Chai 2 AI模型,从零开始设计全长抗体和其他治疗性分子,在早期测试中实现高成功率,并将开发时间从数年到几周缩短。 The company uses its Chai 2 AI model to design full-length antibodies and other therapeutic molecules from scratch, achieving high success rates in early testing and cutting development time from years to weeks. 该基金将支持扩大其AI平台,并推进药物发现,以达到具有挑战性的目标。 The funds will support expanding its AI platform and advancing drug discovery for challenging targets.